Understand the source comparison
Hexarelin Peptide Stacking: Protocol Comparison
Hexarelin + CJC-1295 (no DAC) GHRH priming amplifies ghrelin-induced GH pulse by 180–240% Low. Distinct receptor pathways 5 days on / 4 days off hexarelin; CJC daily or 3×/week Gold standard stack. CJC sustains GH between hexarelin pulses without receptor over
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hexarelin + CJC-1295 (no DAC)
- GHRH priming amplifies ghrelin-induced GH pulse by 180–240%
- Low. Distinct receptor pathways
- 5 days on / 4 days off hexarelin; CJC daily or 3×/week
- Gold standard stack. CJC sustains GH between hexarelin pulses without receptor overlap.
- Hexarelin + Ipamorelin
- Both target GHS-R1a but ipamorelin's lower affinity reduces cumulative saturation
- Moderate. Same receptor, dose-dependent
- Hexarelin 5 on / 4 off; ipamorelin on off-days only at 200 mcg
- Works if ipamorelin is strictly limited to hexarelin washout periods. Concurrent use accelerates desensitisation.
- Hexarelin + MK-677
- Pulsatile (hexarelin) + continuous (MK-677) GH elevation
- High if run concurrently. Both saturate GHS-R1a
- MK-677 during hexarelin off-cycles; avoid overlapping administration
- Effective for maintaining IGF-1 elevation, but concurrent dosing blunts hexarelin response within 10 days.
- Hexarelin + GHRP-2
- Redundant pathway. Both peptides compete for the same receptor
- Very high. Additive GHS-R1a saturation
- Avoid stacking; use GHRP-2 as hexarelin substitute, not concurrent
- No synergy. Running both doubles receptor load without amplifying GH output meaningfully.
- Hexarelin + CJC-1295 DAC + Ipamorelin
- Triple synergy: GHRH baseline + ghrelin pulse + ipamorelin maintenance
- Moderate. Ipamorelin adds receptor load
- CJC-DAC weekly; hexarelin 5 on / 4 off; ipamorelin alternating days
- Advanced stack. CJC-DAC provides 7-day GHRH coverage; hexarelin pulses peak GH; ipamorelin fills gaps. Requires disciplined cycling.